ENANTA Pharmaceuticals, Inc.
500 Arsenal Street
Watertown, Massachusetts
02472
Tel: 617.607.0800
Fax: 617.607.0530
www.enanta.com

For Immediate Release

CONTACT:
Paul Kidwell
617-296-3854
paul_kidwell@hotmail.com

News Release

Enanta Pharmaceuticals Appoints Robert Kamen to Company's Scientific Advisory Board

Dr. Kamen, a leading expert in bioresearch will advise Company on discovery/pre-clinical research activities

WATERTOWN, Mass., October 2, 2002 - Enanta Pharmaceuticals, Inc. (www.enanta.com), a chemistry-driven biopharmaceutical company developing macrolide antibiotics and immunosuppressants, announced today that it has appointed Robert Kamen, Ph.D. to the Company's Scientific Advisory Board.

"Enanta is excited to have such a recognized leader in biotechnology serve as a key member of our Scientific Advisory Board," commented Spiros Jamas, President and CEO of Enanta Pharmaceuticals. "Dr. Kamen's unique combination of molecular biology research and drug development expertise will be invaluable to the Company as we select appropriate biological targets for application with our chemistry capabilities."

"Enanta's strength in chemistry and its integration with biology in the drug discovery process represents an exciting new opportunity to develop improved therapeutics for important diseases such as asthma and respiratory infections," Dr. Kamen stated.

"Dr. Kamen's extensive commercial and strategic drug discovery experience make him ideally suited to contribute towards Enanta's ongoing success," said Dr. Greg Verdine, Chairman, Enanta Scientific Advisory Board. "Dr. Kamen's track record in directing research for global pharmaceutical companies strongly enhances our existing scientific capabilities."

Dr. Kamen most recently served as President, Abbott Bioresearch Center and Divisional Vice President, Discovery Research, Abbott Laboratories from where he retired in Spring 2002. During his tenure at Abbott, Dr. Kamen was responsible for Abbott's bioresearch and biologics production unit in Worcester, Mass. He also served on Abbott Pharmaceuticals Executive Management Committee. He continues to serve Abbott in a part time capacity as senior scientific consultant. Prior to joining Abbott, Dr. Kamen was president of BASF Bioresearch Corporation from 1991-2001. Additionally, he held various senior scientific and management positions with Genetics Institute, Inc., clinical

research activities and established the Company's clinical development department. including, Director of Research, Vice President of Research, and Senior Vice President, Scientific Affairs. While at Genetics Institute he was responsible for discovery/pre- Under Dr. Kamen's scientific leadership, Genetics Institute developed and marketed the following pharmaceutical products: Epogin® (rhEPO marketed by Chugai (Antihemophilic Factor, recombinant, marketed by Baxter worldwide), Neumega® (Oprelvekin, rhIL-11, marketed by Wyeth) and BeneFIXTM (Coagulation factor IX, recombinant, marketed by Wyeth).

Dr. Kamen's work at BASF/Abbott produced the human anti-TNF monoclonal antibody D2E7, the first fully human antibody to be developed, which was submitted to the FDA for approval early in 2002; the anti-IL-12 human antibody J695 (phase II), and three oncology product candidates which were outlicensed to Ilex Oncology (ILX-651 is in phase I clinical trials).

Additionally, Dr. Kamen has authored or co-authored over 50 peer-reviewed articles in major scientific journals. Dr. Kamen holds a Ph.D., Biochemistry and Molecular Biology, from Harvard University Graduate School of Arts and Sciences and an A.B., Biophysics, Amherst College.

About Enanta

Headquartered in Watertown, Mass., Enanta Pharmaceuticals is using its breakthrough chemistry technology -- *Drug Morphing™* and *Peptide Morphing®* -- to create new intellectual properties by transforming existing drugs, natural products, and biologically active peptides into novel, small-molecule drugs. The Company is initially focusing on new chemical entities derived from existing drugs that address significant unmet medical needs: (a) new-generation macrolide antibiotics to overcome bacterial resistance; and (b) anti-inflammatory drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases.

# # # #